I. Vergote

2.6k citations

77 papers · 1.7k indexed · 1 hit paper · h-index 18

Impact in

Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment
Obstetrics and Gynecology top 0.5%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments

Papers in

Reproductive Medicine 48
- Ovarian cancer diagnosis and treatment 46
Obstetrics and Gynecology 12
- Endometrial and Cervical Cancer Treatments 11

Co-authors: D. Timmerman T. Bourne L. Valentin William P. Collins Herman Verrelst Frédéric Amant A.A.W. Peters J. Baptist Trimbos
Journals: Annals of Oncology (14 papers)International Journal of Gynecological Cancer (10 papers)European Journal of Cancer (8 papers)Gynecologic Oncology (8 papers)British Journal of Cancer (5 papers)
Partner nations: Belgium Germany United States

In The Last Decade

I. Vergote

74 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group 2000 · 674 citations

Peers

Countries citing papers authored by I. Vergote

Since Specialization

Citations

This map shows the geographic impact of I. Vergote's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Vergote with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Vergote more than expected).

Fields of papers citing papers by I. Vergote

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Vergote. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Vergote. The network helps show where I. Vergote may publish in the future.

Co-authors

The 25 scholars most cited alongside I. Vergote, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with I. Vergote Line = papers co-authored together I. Vergote links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Single-cell profiling in ovarian germ cell and sex cord-stromal tumours British Journal of Cancer ·Chung‐Lin Chung, Anne‐Sophie Van Rompuy, G. Monnet, Gloria Marquina, José Luis Valdez-Medina, Siel Olbrecht, Tyler Kjorstad, Thaïs Baert, Toon Van Gorp, I. Vergote, Diether Lambrechts, Els Van Nieuwenhuysen	2025	0
2	530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety Annals of Oncology ·Andrew Martin, Bhavana Pothuri, I. Vergote, Horst Winterhoff, Mansoor R. Mirza, Business Europe, Jingyi Huang, Gilles Freyer, Floor Backes, Klaus Baumann, Andrés Redondo, R. G. Moore, Christof Vulsteke, Larissa Rodrigues Vieira, Sarah Kresser, Elãyne Pereira Silva, Natalie Compton, B.J. Monk	2022	16
3	579P A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detection Annals of Oncology ·Duva Karunakaran, Pierre Saintigny, Éric Pujade-Lauraine, Marguerite C. Voegele, Susan Miller-Samuel, Matthias B chler, N. Colombo, Alexandre Harlé, Pauline Gilson, 孙麟祥, Petter Storsten, P Harter, Sandro Pignata, Andrew Martin, Christian Schauer, Ha Kyeong Kim, I. Vergote, Trine Juhler‐Nøttrup, Hamza Polat, Marta Bahlai	2022	1
4	739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial Annals of Oncology ·Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, Tsui-Shan Chau, Bruno Botelho Pereira, Saverio Cinieri, 뉴엔티민후옌, Gerhard Bogner, Hiroyuki Yoshida, I. Vergote, N. Colombo, Inge Margrethe Poulsen, R. Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Eric Pujade‐Lauraine, Laure Favier, I. L. Ray-Coquard	2021	1
5	833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer Annals of Oncology ·David M. O’Malley, Debra L. Richardson, I. Vergote, Lucy Gilbert, Cesar M. Castro, Diane Provencher, Ursula A. Matulonis, Gina Mantia-Smaldone, Lainie P. Martin, Patrick A. Zweidler‐McKay, Kathleen N. Moore	2020	9
6	LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line Annals of Oncology ·Nicoletta Colombo, Angiolo Gadducci, Jalid Sehouli, Elena Biagioli, Laura Viviana Sierra Barrera, Mohammad Mehdi Kambari, Ana Montes, Nelleke Ottevanger, Alain G. Zeimet, I. Vergote, 三男浅川, Alessandra Baldoni, Germana Tognon, Andrea De Censi, Ganggang Zhai, Radoslav Chekerov, Johanna Mäenpää, Eliana Rulli, Roldano Fossati, Andrés Poveda	2020	16
7	LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study Annals of Oncology ·Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Panagiotis Bravos, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Tanya Girova, Reshma Rangwala, Signe Diness Vindeløv, Jonli Tunstall, Jeffrey R. Harris, Leonardo Nicacio, Baard Ingvaldsen, Kimberly Cruz, B.J. Monk, I. Vergote	2020	17
8	Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179 Annals of Oncology ·Ana Oaknin, I. Vergote, Isabelle Ray‐Coquard, Alexandra Léary, Ankur Pandey, Nicole Concin, Yang Sikun, Christophe Massard, Lorena Fariñas-Madrid, Els Van Nieuwenhuysen, Angelika Lahr, Ishigaki Hisakazu, Simona Rossomanno, Peter Arne Gerber, Tapan K. Nayak, Florian Heil, Christophe Boetsch, Ary Muhammad, G. Chedd, Oliver Krieter	2017	6
9	PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) Annals of Oncology ·Bristi Basu, Charlie Gourley, Hani Gabra, I. Vergote, James D. Brenton, Lars Abrahmsén, Fadilla Maulina Sari, Mia von Euler, Babette Lorra	2016	6
10	Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases European Journal of Cancer ·Márcia Armentano Clark REIS, Ph. Moerman, Frédéric Amant, Karin Leunen, P. Neven, I. Vergote	2013	57
11	Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer British Journal of Cancer ·Gerda Hofstetter, Astrid Berger, E. Schuster, Andrea Wolf, 正吉広瀬, I. Vergote, Isabelle Cadron, Jalid Sehouli, Elena Ioana Braicu, Sven� Mahner, P Speiser, Christian Marth, Alain G. Zeimet, Hanno Ulmer, Robert Zeillinger, Nicole Concin	2011	37
12	Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB–IV epithelial ovarian cancer Gynecologic Oncology ·Dimitrios Tsolakidis, Frédéric Amant, Toon Van Gorp, Karin Leunen, Patrick Neven, I. Vergote	2009	31
13	Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2-IIIB International Journal of Gynecological Cancer ·Evagelia Mavroforou, Sigrid Stroobants, Frédéric Amant, Patrick Neven, E. Van Limbergen, I. Vergote	2008	3
14	HPV induced ovarian squamous cell carcinoma: case report and review of the literature Archives of Gynecology and Obstetrics ·Dmitry E. Shybanov, Frédéric Amant, Ph. Moerman, I. Vergote	2007	26
15	Classification of radical hysterectomy adopted by the Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer1 International Journal of Gynecological Cancer ·Concetta L. Zak, I. Vergote, J. Baptist Trimbos, Frédéric Amant, Nadeem Siddiqui, Ana del Río Lechuga, R.H.M. Verheijen, Paolo Zola	2007	25
16	Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy International Journal of Gynecological Cancer ·Martine Piccart, Anne Floquet, Giovanna Scarfone, Pax H.B. Willemse, Janusz Emerich, I. Vergote, L. Giurgea, C. Coens, Ahmad Awada, Jan B. Vermorken	2003	83
17	Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group European Journal of Cancer ·Matti Aapro, F.H. van Wijk, M.E.L. van der Burg, W ten Bokkel Huinink, I. Vergote, J P Guastalla, R. Rosso, A Kobierska, L.V.A.M. Beex, M Namer, Yordany Pérez González, Jan B. Vermorken	2003	1
18	Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women European Journal of Cancer ·I. Vergote	2002	4
19	Clinical management of ovarian cancer New England Journal of Medicine ·JA Ledermann, Espinoza Matos, Stuart Kaye, I. Vergote	2001	3
20	Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group Ultrasound in Obstetrics and Gynecology ·D. Timmerman, L. Valentin, T. Bourne, William P. Collins, Herman Verrelst, I. Vergote Hit paper breakdown →	2000	674

About I. Vergote

I. Vergote is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Cancer Research and Genetics, having authored 77 papers that have together received 1.7k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (46 papers), PARP inhibition in cancer therapy (11 papers), Endometrial and Cervical Cancer Treatments (11 papers), BRCA gene mutations in cancer (6 papers), HER2/EGFR in Cancer Research (6 papers), Estrogen and related hormone effects (6 papers), Cancer Genomics and Diagnostics (5 papers) and Intraperitoneal and Appendiceal Malignancies (5 papers). The work is most often cited by research in Reproductive Medicine (1.1k citations), Obstetrics and Gynecology (755 citations), Surgery (662 citations), Oncology (392 citations) and Pathology and Forensic Medicine (105 citations). I. Vergote has collaborated with scholars based in Belgium, Germany and United States. Frequent co-authors include D. Timmerman, T. Bourne, L. Valentin, William P. Collins, Herman Verrelst, Frédéric Amant, A.A.W. Peters, J. Baptist Trimbos, Gemma G. Kenter and Katja N. Gaarenstroom. Their work appears in journals such as Annals of Oncology, International Journal of Gynecological Cancer, European Journal of Cancer, Gynecologic Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact